Value Sense
GLUE

Monte Rosa Therapeutics, Inc. (GLUE)

Last Price$5.80.5%
Market Cap$358.2M

GLUE Rating

GLUE Quality rating
5.7
How this score works?
GLUE Quality rating performance

GLUE Intrinsic Value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 24, 2025 GLUE Relative Value is $7.2, which is undervalued by 23.0%, compared to current share price of $5.8.
DCF Value vs Current Share Price
As of Mar 24, 2025 GLUE DCF Value is N/A, which is undervalued by N/A, compared to current share price of $5.8.
Methodology
Price per share, $
GLUE
Intrinsic value$7.2
Undervalued by23.1%
Current share price
5.8
Relative value
7.2
DCF value
not available

GLUE Share Price History

1W (13.4%)
1M (0.2%)
6M 2.5%
YTD 2.1%
1Y (31.1%)
3Y (49.9%)
5Y (72.5%)
10Y (72.5%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!

GLUE Stock Metrics

Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
Market Cap
$358.2M
Enterprise Value
$28.7M
LTM Revenue
$75.6M
LTM Free Cash Flow
$38.0M
Shares Outstanding
61M
Employees
N/A
Growth (CAGR)
Revenue 5Y
N/A
Operating Income 5Y
N/A
EPS 5Y
N/A
Free Cash Flow 5Y
N/A
Forward Revenue 2Y
N/A
Forward EPS 2Y
(61.74%)
Profitability
Gross margin
94.8%
EBIT margin
(107.3%)
Net income margin
(96.1%)
OCF margin
55.5%
FCF margin
50.3%
FCF / Net Income
(52.3%)
Intrinsic Value
Intrinsic Value
$7.2 (23.1% undervalued)
DCF Value
N/A
Relative Value
$7.2
Peter Lynch fair value
$27.6
Ben Graham fair value
$48.4
Reverse DCF (implied FCF growth)
(0.9%)
EPV, % of EV
(209.8%)
Valuation (LTM)
EV / Revenue
0.4x
EV / EBIT
(0.4x)
P / FCF
9.4x
P / E
(4.9x)
P / BV
1.6x
PEG
0.1x
FCF Yield
10.6%
Return on Capital
ROE
(33.9%)
ROA
(19.3%)
ROIC
(176.7%)
ROCE
(30.1%)
ROE 5Y avg
(31.4%)
ROIC 5Y avg
(351.1%)
ROCE 5Y avg
(351.1%)
Financial Health
Cash & Short-term Investments
$372.1M
Net Debt
($329.4M)
Net Debt / FCF
(8.7x)
EBIT / Interest
N/A
Total Debt / Equity
19.2%
Dividends
Dividends per share (DPS)
$0.0
DPS 5Y CAGR
N/A
Dividend Yield
0.0%
FCF Payout ratio
0.0%
Ex-dividend date
Earnings
Next earnings date
Jan 01, 1970
Last Revenue surprise
BEAT by 71.4%
Last EPS surprise
BEAT by (55.2%)
Next EPS YoY growth
7.4%
Last 10 earnings
8 Beat & 2 Miss

GLUE Stock Financials

GLUE Income Statement Metrics

Annual
Quarterly
LTM

Revenue

$0.0 N/A

Operating Income

($143,311,000.0) +27.5% YoY

Net Income

($135,352,000.0) +29.4% YoY

GLUE Cash Flow Statement Metrics

Annual
Quarterly
LTM

Operating Cash Flow (OCF)

($43.8M) -52.6% YoY

Capital Expenditure (CAPEX)

($19.0M) +47.5% YoY

Free Cash Flow (FCF)

($62.8M) -40.4% YoY

GLUE Income Statement Overview

Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Gross profit
$6,222.0K (27.3%) YoY
0.0% margin
Cost of revenue
$6,222.0K (27.3%) YoY
Operating expenses
$143.3M 27.5% YoY
Net income
$135.4M 29.4% YoY
0.0% margin
Other: $129.1M
R&D
$105.1M 23.5% YoY
0.0% of revenue
SG&A
$32.0M 17.3% YoY
0.0% of revenue

GLUE Balance Sheet Overview

Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$303.8M
Current assets ($236.2M, 77.8% of total)
Cash & ST investments
$232.4M (76.5%)
Accounts receivables
$505.0K (0.2%)
Other current assets
$3,294.0K (1.1%)
Non-current assets ($67.5M, 22.2% of total)
Other non-current assets
$4,932.0K (1.6%)
Financial position
Net Debt
($186.4M)
$232.4M$46.0M
Cash & Short-term Investments
Total Debt
Quick ratio
5.0x
Net Debt to Free Cash Flow
3.0x
Debt to Equity ratio
25.7%

GLUE Stock Ratios

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Revenue growth
EPS growth
Gross margin
Free Cash Flow margin
Net Debt to FCF
FCF to Interest
ROIC
Shareholder yield

GLUE Earnings Surprises

Crunching data... Almost there!

GLUE Dividends

GLUE Dividend Yield

Crunching data... Almost there!

GLUE Dividend Per Share

3Y
10Y
30Y
Annual
Quarterly
LTM
1Y Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
10Y CAGR
N/A

Competing with GLUE

Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name
Market Cap
Quality rating
Intrinsic value
1Y Return
Revenue
Free Cash Flow
Revenue growth
FCF margin
Gross margin
ROIC
Total Debt to Equity
GLUE
$358.2M
5.7
$7.2
23.1% undervalued
(31.1%)
$75.6M
$38.0M
764.1%
50.3%
94.8%
(176.7%)
19.2%
VRTX
$131.8B
5.8
$186.0
63.7% overvalued
23.0%
$11.0B
($790.3M)
11.5%
(7.2%)
86.1%
(15.0%)
10.7%
REGN
$71.1B
6.4
$1,034.1
56.4% undervalued
(31.1%)
$14.2B
$3,597.2M
8.3%
25.3%
84.5%
25.7%
5.7%
ARGX
$43.1B
6.3
$161.4
73.4% overvalued
52.6%
$3,154.8M
($58.8M)
157.1%
(1.9%)
74.8%
67.0%
0.7%
ALNY
$37.4B
5.2
$92.7
68.1% overvalued
91.2%
$2,248.2M
($42.6M)
23.0%
(1.9%)
85.6%
(7.2%)
1,931.9%
BNTX
$24.2B
6.0
$193.7
92.5% undervalued
8.2%
€2,751.1M
(€229.8M)
(28.0%)
(8.4%)
80.3%
(37.8%)
1.3%
RPRX
$15.1B
5.5
$68.9
104.3% undervalued
14.9%
$2,263.9M
$2,769.0M
(3.8%)
122.3%
73.9%
14.5%
73.6%
SMMT
$15.0B
6.0
$0.6
97.2% overvalued
530.8%
$0.0
($142.1M)
N/A
N/A
N/A
(3,335.4%)
1.9%
UTHR
$14.3B
7.8
$542.3
69.6% undervalued
31.0%
$2,877.4M
$1,080.6M
23.6%
37.6%
89.2%
65.4%
4.7%
BMRN
$13.7B
6.8
$50.8
29.4% overvalued
(16.8%)
$2,850.5M
$475.4M
17.8%
16.7%
78.6%
11.0%
10.7%
BGNE
$1,846.9M
5.5
$2,609.6
1,051.1% undervalued
39.9%
$3,316.8M
($1,041.0M)
50.5%
(31.4%)
83.7%
(43.2%)
32.1%

FAQ

What is Monte Rosa Therapeutics, Inc. (GLUE) stock rating?

As of today, Monte Rosa Therapeutics, Inc. has a stock rating of 6 (out of 10), which is considered Good.

is Monte Rosa Therapeutics, Inc. (GLUE) a good stock to buy?

As of today, Monte Rosa Therapeutics, Inc. has a Good stock rating, which is 23.1% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.